4503 Astellas Pharma
- 1487.0
- -26.5-1.75%
Astellas Pharma News
Nikkei Average Contribution Ranking (advance closing) ~ The Nikkei Average fell for the first time in 4 days, and East Elec was pushed down by about 72 yen per brand
The number of gains and falls of the Nikkei average constituent stocks as of closing 17 days ago was 109 stocks with price increases, 115 stocks with price drops, and 1 stock unchanged. The Nikkei Average fell for the first time in 4 days. The forward market transaction was closed at 38782.08 yen (estimated turnover of 920 million shares), which was 138.18 yen lower (-0.36%) compared to the previous day. The US stock market fell on the 16th. The Dow average depreciated by 38.62 dollars (-0.10%) to 39869.38 dollars, and the Nasdaq depreciated by 44.07 points (-0.26%) to 1669
Convertible Stock List (Part 2) [Parabolic Signal Convertible Stock List]
○List of sales conversion stocks market code stock name closing price SAR Tokyo Stock Exchange Prime ＜1377＞ Sakata seed 3600 3700 ＜1414＞ show bond 6065 6234 ＜1417＞ Miraitone 1849 2008 ＜1726＞ Br. HD 355 367 ＜1821＞ Misumi Construction
Nikkei Average Contribution Ranking (big draw) ~ The Nikkei Average continued to rise drastically for 3 days, and TOELEC and Recruit HD were boosted by about 219 yen with 2 brands
The number of gains and falls of the Nikkei Average constituent stocks at the time of the big closing on the 16th was 96 stocks with price increases and 126 stocks with price drops unchanged. The US stock market continued to rise on the 15th. The Dow average closed at 39908.00 dollars, which was 349.89 dollars higher (+ 0.88%), the NASDAQ was 231.21 points higher (+ 1.40%) at 16742.39, and the S&P 500 closed at 5308.15, which was 61.47 points higher (+ 1.17%). Consumer Price Index (CPI) growth slowed in April
Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript Summary
The following is a summary of the Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript:Financial Performance:Astellas Pharma reported a revenue decrease of 2% YoY due to Lexiscan generics' im
MonoAI, Hope, etc. [Emerging Markets Press Release]
＜3727＞APLIX earnings forecast revisions, current fiscal year business profit forecast 219 million yen ← 264 million yen ＜4262＞acquisition of shares in Doors, which handles the operation of the Nifty Life exterior wall painting specialty site “Exterior Wall Painting Window,” and making it a subsidiary ＜4563＞Anges 1st Unsecured Convertible Bonds Type Stock Acquisition Rights Corporate Bonds (with conversion price correction clauses) number of shares issued since the 13th, 736,614 shares ＜4579＞LaQuoria Drug Discovery Exterior Wall Remodeling Support Agreement Businesses Consolidated subsidiary that handles it
Corbus Pharmaceuticals a New Outperform at RBC on Cancer, Obesity Assets
Nikkei Average Contribution Ranking (advance closing) - The Nikkei Average continued to rise slightly, boosted by about 72 yen for the 2 brands SoftBank G and KDDI
The number of gains and falls of the Nikkei Average constituent stocks as of closing 13 days ago was 2 stocks unchanged: 85 stocks with price increases and 138 stocks with price drops. The Nikkei Average continued to rise slightly. The front-end transaction was closed at 38243.59 yen (estimated turnover of 1.01 billion shares), which was 14.48 yen higher (+0.04%) compared to the previous business day. The US stock market was mixed on the 10th. The Dow average rose by $125.08 (+ 0.32%) to $39512.84, and the Nasdaq depreciated 5.39 points (-0.03%) to 163
Lupin Relaunches Mirabegron ER Tablets in US
Lupin (NSE:LUPIN, BOM:500257) has relaunched and resumed shipments of its Mirabegron ER Tablets, 25 mg, in the US, according to a Friday filing to the BSE. The relaunch comes in the wake of the US Cou
Nikkei average contribution ranking (advance closing) ~ The Nikkei average rebounded, and Omron boosted by about 21 yen with 1 brand
The number of gains and falls of the Nikkei Average constituent stocks at the time of closing 9 days ago was 184 stocks with price increases, 40 stocks with price drops, and 1 stock unchanged. The Nikkei Average rebounded. The front-end transaction was closed at 38392.10 yen (estimated turnover of 840 million shares), which was 189.73 yen higher (+0.50%) compared to the previous day. The US stock market on the 8th was mixed. The Dow average rose by $172.13 (+ 0.44%) to $39056.39, and the Nasdaq depreciated 29.80 points (-0.18%) to 16302.76
J-Front, Kissei Pharmaceutical Industries, etc. (additional) Rating
Target Stock Price Change Code | Stock Name | Securities Company | Conventional | After Change |------|-----------------------------|----------|-------|＜4205＞|Nippon Zeon |SMBC Nikko |1500 yen |1600 yen |＜8056＞|BIPROGY | SMBC Nikko | 3600 yen
Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
- 154,000 square-foot lab and office facility creates a central location for Astellas' West Coast cell and gene therapy research and business development operations TOKYO and SAN FRANCISCO, May 8, 2
Nikkei Average Contribution Ranking (big draw) ~ The Nikkei Average continued to decline slightly, and Fast Rite and TDK were pushed down by about 57 yen with 2 stocks
The number of gains and falls of the Nikkei average constituent stocks at the time of the 2-day closing was 2 stocks unchanged, 100 stocks with price increases and 123 stocks with price drops. The US stock market was mixed on May 1. The Dow average closed at 37903.29 dollars, which was 87.37 dollars higher (+ 0.23%), the NASDAQ was 52.34 points lower (-0.33%) at 15605.48, and the S&P 500 closed at 5018.39, which was 17.30 points lower (-0.34%). Private sector employment statistics are mixed to beat expectations
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR programs targeting solid tumors -TOKYO and SAN DIEGO, May 1, 2024 /PRNewswire/ -- Astellas Pharma Inc.
Poseida Gains on Cell Therapy Pact With Astellas
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences
By Chris Wack Poseida Therapeutics shares were up 18% to $2.86 after the company said it entered into a research collaboration and license agreement with Astellas Pharma's Xyphos Biosciences subsidia
Nikkei Average Contribution Ranking (advance closing) ~ The Nikkei Average fell for the first time in 3 days, and Fast Rite was pushed down by about 49 yen per brand
The number of gains and falls of the Nikkei Average constituent stocks at the time of closing 1 day ago was 44 stocks with price increases, 181 stocks with price drops, and 0 stocks unchanged. The Nikkei Average fell for the first time in 3 days. The forward market transaction was closed at 38189.54 yen (estimated turnover of 880 million shares), which was 216.12 yen lower (-0.56%) compared to the previous day. The US stock market fell on April 30. The Dow average depreciated by $570.17 (-1.49%) at $37815.92, and the Nasdaq depreciated by 325.26 points (-2.04%)
Convertible Stock List (Part 1) [Parabolic Signal Convertible Stock List]
○List of trading stocks market code stock name closing price SAR Tokyo Stock Exchange Prime ＜1377＞ Sakata seed 3605 3505 ＜1379＞ Hokuto 1829 1783 ＜1773＞ YTL 97 77 ＜1814＞ Daisue Ken 1552 1500 ＜1820＞ Nishimatsuken 4543 42 42
Earnings Call Summary | ASTELLAS PHARMA(ALPMF.US) Q4 2023 Earnings Conference
The following is a summary of the Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript:Financial Performance:Astellas reported a year-on-year revenue of JPY1,603.7 billion, marking an increas
Nikkei average contribution ranking (advance closing) ~ The Nikkei Average rebounded, and TOEREC boosted by about 61 yen with 1 brand
The number of gains and falls of the Nikkei Average constituent stocks as of closing 26 days ago was 121 stocks with a price increase and 101 stocks with a price drop of 3 stocks unchanged. The Nikkei Average rebounded. The front-end transaction was closed at 37780.35 yen (estimated volume of 740 million shares), which was 151.87 yen higher (+0.40%) compared to the previous day. The US stock market declined on the 25th. The Dow average depreciated by 375.12 dollars (-0.98%) at 38085.80 dollars, and the NASDAQ depreciated 100.99 points (-0.64%) at 15611.
Nomura FuHD, MinebeaMitsumi, etc. (added) Rating
Downgrading-Bearish Code | Stock Name | Securities Company | Conventional | After Change |------|--------------|--------------|--------------|<2337＞|Ichigo |Morgan S | “Over W” | “Equal W” | Target Stock Price Change Code | Stock Name | Securities Company | Conventional | After Change |----
Analysis
Price Target
No Data
